

Huseyin Naci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5837821/publications.pdf>

Version: 2024-02-01

105
papers

4,735
citations

159358

30
h-index

102304

66
g-index

105
all docs

105
docs citations

105
times ranked

7097
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. <i>BMJ, The</i> , 2013, 347, f5577-f5577.	3.0	479
2	Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. <i>BMC Medicine</i> , 2013, 11, 159.	2.3	427
3	Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. <i>BMJ: British Medical Journal</i> , 2017, 359, j4530.	2.4	423
4	From "retailers" to health care providers: Transforming the role of community pharmacists in chronic disease management. <i>Health Policy</i> , 2015, 119, 628-639.	1.4	294
5	Distribution of road traffic deaths by road user group: a global comparison. <i>Injury Prevention</i> , 2009, 15, 55-59.	1.2	256
6	Comparative Tolerability and Harms of Individual Statins. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 390-399.	0.9	236
7	How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 randomised controlled trials assessing exercise and medication effects on systolic blood pressure. <i>British Journal of Sports Medicine</i> , 2019, 53, 859-869.	3.1	207
8	Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 641-657.	0.8	170
9	Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 626.	3.8	148
10	Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis. <i>BMJ: British Medical Journal</i> , 2019, 366, l5221.	2.4	117
11	Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. <i>British Journal of Sports Medicine</i> , 2015, 49, 1414-1422.	3.1	89
12	Expanding the role of community pharmacists: Policymaking in the absence of policy-relevant evidence?. <i>Health Policy</i> , 2013, 111, 135-148.	1.4	78
13	Prognostic Significance of Left Ventricular Noncompaction. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e009712.	1.3	74
14	Evaluation of Wellness Determinants and Interventions by Citizen Scientists. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 121.	3.8	71
15	The Critical Role Of Observational Evidence In Comparative Effectiveness Research. <i>Health Affairs</i> , 2010, 29, 1826-1833.	2.5	63
16	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. <i>European Heart Journal</i> , 2016, 37, 747-754.	1.0	62
17	Cost Implications of Using Different ECG Criteria for Screening Young Athletes in the United Kingdom. <i>Journal of the American College of Cardiology</i> , 2016, 68, 702-711.	1.2	59
18	Generating comparative evidence on new drugs and devices before approval. <i>Lancet, The</i> , 2020, 395, 986-997.	6.3	59

#	ARTICLE	IF	CITATIONS
19	Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 658-670.	0.8	58
20	How Good Is "Evidence" from Clinical Studies of Drug Effects and Why Might Such Evidence Fail in the Prediction of the Clinical Utility of Drugs?. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 169-189.	4.2	58
21	Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. <i>BMJ, The</i> , 2014, 349, g5741-g5741.	3.0	55
22	Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval. <i>Milbank Quarterly</i> , 2017, 95, 261-290.	2.1	52
23	Generating comparative evidence on new drugs and devices after approval. <i>Lancet, The</i> , 2020, 395, 998-1010.	6.3	52
24	The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. <i>Journal of Medical Economics</i> , 2010, 13, 78-89.	1.0	47
25	Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment. <i>Medical Decision Making</i> , 2015, 35, 859-871.	1.2	44
26	Impact of the International Recommendations for Electrocardiographic Interpretation on Cardiovascular Screening in Young Athletes. <i>Journal of the American College of Cardiology</i> , 2017, 70, 805-807.	1.2	44
27	Evidence of comparative efficacy should have a formal role in European drug approvals. <i>BMJ: British Medical Journal</i> , 2011, 343, d4849-d4849.	2.4	41
28	Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 350-357.	2.3	41
29	Balloon Dilatation and Stenting for Aortic Coarctation. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	40
30	The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements. <i>Clinical Trials</i> , 2018, 15, 219-229.	0.7	38
31	Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States. <i>Milbank Quarterly</i> , 2020, 98, 1219-1256.	2.1	37
32	Why the drug development pipeline is not delivering better medicines. <i>BMJ, The</i> , 2015, 351, h5542.	3.0	34
33	Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval. <i>JAMA Internal Medicine</i> , 2021, 181, 490.	2.6	32
34	Planning a future randomized clinical trial based on a network of relevant past trials. <i>Trials</i> , 2018, 19, 365.	0.7	31
35	Comparative effects of statins on major cerebrovascular events: a multiple-treatments meta-analysis of placebo-controlled and active-comparator trials. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 299-306.	0.2	30
36	Medication Affordability Gains Following Medicare Part D Are Eroding Among Elderly With Multiple Chronic Conditions. <i>Health Affairs</i> , 2014, 33, 1435-1443.	2.5	30

#	ARTICLE	IF	CITATIONS
37	An Assessment of the Methodological Quality of Published Network Meta-Analyses: A Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0121715.	1.1	28
38	Evidence-Based Prescribing. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 787-792.	0.9	27
39	Economic evaluation of mental health interventions: an introduction to cost-utility analysis. <i>Evidence-Based Mental Health</i> , 2016, 19, 49-53.	2.2	27
40	QALYs in cost-effectiveness analysis: an overview for cardiologists. <i>Heart</i> , 2015, 101, 1868-1873.	1.2	25
41	A review of NICE appraisals of pharmaceuticals 2000â€“2016 found variation in establishing comparative clinical effectiveness. <i>Journal of Clinical Epidemiology</i> , 2019, 105, 50-59.	2.4	25
42	Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. <i>Journal of Evaluation in Clinical Practice</i> , 2010, 16, 744-755.	0.9	23
43	Raising the bar for market authorisation of new drugs. <i>BMJ, The</i> , 2012, 345, e4261-e4261.	3.0	23
44	Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies. <i>Pharmacoeconomics</i> , 2020, 38, 1297-1308.	1.7	23
45	History Bias, Study Design, and the Unfulfilled Promise of Pay-for-Performance Policies in Health Care. <i>Preventing Chronic Disease</i> , 2016, 13, E82.	1.7	22
46	Health policy in times of austerityâ€“A conceptual framework for evaluating effects of policy on efficiency and equity illustrated with examples from Europe since 2008. <i>Health Policy</i> , 2017, 121, 947-954.	1.4	22
47	Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. <i>Lancet Oncology, The</i> , 2022, 23, 514-520.	5.1	22
48	Pharmacy interventions on COVID-19 in Europe: Mapping current practices and a scoping review. <i>Research in Social and Administrative Pharmacy</i> , 2022, 18, 3338-3349.	1.5	20
49	Raising the bar for using surrogate endpoints in drug regulation and health technology assessment. <i>BMJ, The</i> , 2021, 374, n2191.	3.0	19
50	Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19. <i>BMJ, The</i> , 2020, 371, m3869.	3.0	16
51	Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval. <i>JAMA Internal Medicine</i> , 2021, 181, 1673.	2.6	16
52	Assessing comparative effectiveness of new drugs before approval using prospective network meta-analyses. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 812-816.	2.4	15
53	Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs. <i>Value in Health</i> , 2020, 23, 319-327.	0.1	15
54	Recent Trends and Potential Drivers of Non-invasive Cardiovascular Imaging Use in the United States of America and England. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 617771.	1.1	15

#	ARTICLE	IF	CITATIONS
55	The Economics of Health Care Delivery. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 55, 482-488.	0.9	14
56	Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. <i>JAMA Internal Medicine</i> , 2021, 181, 1596-1604.	2.6	14
57	Rethinking the appraisal and approval of drugs for type 2 diabetes. <i>BMJ</i> , 2015, 351, h5260.	3.0	13
58	Productivity losses from road traffic deaths in Turkey. <i>International Journal of Injury Control and Safety Promotion</i> , 2008, 15, 19-24.	1.0	12
59	Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection. <i>Medical Decision Making</i> , 2019, 39, 264-277.	1.2	11
60	Using Indirect Evidence to Determine the Comparative Effectiveness of Prescription Drugs: Do Benefits Outweigh Risks?. <i>Health Outcomes Research in Medicine</i> , 2011, 2, e241-e249.	0.6	10
61	Bicuspid aortic valve disease: systematic review and meta-analysis of surgical aortic valve repair. <i>Open Heart</i> , 2016, 3, e000502.	0.9	10
62	The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation. <i>Clinical Trials</i> , 2018, 15, 243-246.	0.7	10
63	Improving health care services in Northern Cyprus: a call for research and action. <i>European Journal of Public Health</i> , 2012, 22, 754-755.	0.1	9
64	Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis. <i>Journal of Medical Economics</i> , 2012, 15, 293-304.	1.0	9
65	The impact of post-procedural complications on reimbursement, length of stay and mechanical ventilation among patients undergoing transcatheter aortic valve implantation in Germany. <i>European Journal of Health Economics</i> , 2018, 19, 223-228.	1.4	9
66	Comparative fertility and pregnancy outcomes after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE group. <i>BMJ Open</i> , 2019, 9, e028009.	0.8	9
67	European Medicines Agency's Priority Medicines Scheme at 2 Years: An Evaluation of Clinical Studies Supporting Eligible Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 541-552.	2.3	9
68	Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support. <i>Medical Decision Making</i> , 2019, 39, 239-252.	1.2	8
69	Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 189-211.	1.0	8
70	Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials. <i>Heart Failure Reviews</i> , 2020, 25, 161-171.	1.7	8
71	New agreement on branded drugs for the NHS. <i>BMJ: British Medical Journal</i> , 2019, 364, l266.	2.4	7
72	Specialty Drugs – A Distinctly American Phenomenon. <i>New England Journal of Medicine</i> , 2020, 382, 2179-2181.	13.9	7

#	ARTICLE	IF	CITATIONS
73	NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 426-433.	0.2	7
74	No evidence of industry sponsorship bias in statin trials. <i>BMJ, The</i> , 2014, 349, g6579-g6579.	3.0	6
75	Timely publication and sharing of trial data: opportunities and challenges for comparative effectiveness research in cardiovascular disease. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2015, 1, 58-65.	1.8	6
76	What to do (or not to do) when randomization is not possible. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1174-1177.	0.3	6
77	Accelerated access to new drugs and technologies. <i>BMJ: British Medical Journal</i> , 2017, 359, j5387.	2.4	6
78	Inappropriate use of progression-free survival in cancer drug approvals. <i>BMJ, The</i> , 2020, 368, m770.	3.0	6
79	Ethical implications of poor comparative effectiveness evidence: obligations in industry-research partnerships. <i>Lancet, The</i> , 2020, 395, 926-928.	6.3	6
80	Effectiveness of interventions for dementia in low- and middle-income countries: protocol for a systematic review, pairwise and network meta-analysis. <i>BMJ Open</i> , 2019, 9, e027851.	0.8	5
81	Impact of predictive medicine on therapeutic decision making: a randomized controlled trial in congenital heart disease. <i>Npj Digital Medicine</i> , 2019, 2, 17.	5.7	5
82	Study design, result posting, and publication of late-stage cardiovascular trials. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 277-288.	1.8	5
83	NITRATE-CIN Study: Protocol of a Randomized (1:1) Single-Center, UK, Double-Blind Placebo-Controlled Trial Testing the Effect of Inorganic Nitrate on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography for Acute Coronary Syndromes. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 303-309.	1.0	5
84	Communication of Survival Data in US Food and Drug Administration's Approved Labeling of Cancer Drugs. <i>JAMA Internal Medicine</i> , 2021, 181, 1521.	2.6	5
85	Communication of Treatment Rankings Obtained From Network Meta-Analysis Using Data Visualization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 605-608.	0.9	4
86	Cyprus Women's Health Research (COHERE) initiative: determining the relative burden of women's health conditions and related co-morbidities in an Eastern Mediterranean population. <i>BMC Women's Health</i> , 2019, 19, 50.	0.8	4
87	Preventing cardiovascular events with empagliflozin: at what cost?. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 931.	5.5	3
88	Comparative efficacy and complication rates after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE Group. <i>BMJ Open</i> , 2019, 9, e028008.	0.8	3
89	Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisals. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 311-316.	0.2	3
90	The Cyprus Women's Health Research (COHERE) initiative: normative data from the SF-36v2 questionnaire for reproductive aged women from the Eastern Mediterranean. <i>Quality of Life Research</i> , 2022, 31, 2011-2022.	1.5	3

#	ARTICLE	IF	CITATIONS
91	Coverage of New Drugs in Medicare Part D. <i>Milbank Quarterly</i> , 2022, 100, 562-588.	2.1	3
92	A Cost-Utility Analysis of Cryoballoon Ablation versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2018, 11, 2069.	0.5	2
93	Post-Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004-2014. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 846-852.	2.3	2
94	Avoidable costs of stenting for aortic coarctation in the United Kingdom: an economic model. <i>BMC Health Services Research</i> , 2017, 17, 258.	0.9	1
95	Infographic. How does exercise treatment compare with antihypertensive medications?. <i>British Journal of Sports Medicine</i> , 2020, 54, 746-747.	3.1	1
96	Ultraexpensive gene therapies, industry interests and the right to health: the case of onasemnogene abeparvovec in Brazil. <i>BMJ Global Health</i> , 2022, 7, e008637.	2.0	1
97	Use of adherence monitoring in drug contracts tied to outcomes: put patients first. <i>BMJ, The</i> , 2022, 376, e062188.	3.0	1
98	Regulators Should Better Leverage Effectiveness Standards to Enhance Drug Value. <i>Pharmacotherapy</i> , 2014, 34, 1005-1011.	1.2	0
99	Capsule Commentary on Ott et al., Do Statins Impair Cognition? A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Journal of General Internal Medicine</i> , 2015, 30, 347-347.	1.3	0
100	Evidence Required for Drugs Granted Accelerated Approval-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2493.	3.8	0
101	Can we rely on non-randomised studies? Findings from a meta-epidemiological review. <i>European Journal of Public Health</i> , 2019, 29, .	0.1	0
102	The Supercar Stays in the Garage: Factors Preventing Indirect Comparisons of Novel Medicines Targeting the Same Condition. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 333-334.	0.5	0
103	The Coverage in England of US-Approved Cancer Drugs-Reply. <i>JAMA Internal Medicine</i> , 2021, 181, 1263.	2.6	0
104	Putting patients first in medicines regulation?. <i>BMJ, The</i> , 2021, 375, n2883.	3.0	0
105	Study design, result reporting and publication of late-stage cardiovascular trials. <i>European Heart Journal</i> , 2020, 41, .	1.0	0